Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership
The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
Subscribe To Our Newsletter & Stay Updated